Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cimlanod Hemodynamic Study in HFrEF
NCT03357731Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2017
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of cimlanod in heart failure with reduced ejection fraction (HFrEF) (6 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Stroke Volume Index at 5 hours. Started Nov 2017; status: completed.
02
Drugs
cimlanod
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT03357731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03357731.